文献速递抗栓抗凝管理药物不良反应与药物警戒

临床实践中直接口服抗凝药与华法林治疗非瓣膜性房颤的疗效比较随时间因通道效应而变化

Comparative treatment effects of direct oral anticoagulants versus warfarin for nonvalvular atrial fibrillation in clinical practice vary over time due to channelling.
PubMed 文献 · Br J Clin Pharmacol · 2026-10-30

该研究基于英国临床实践研究数据链Aurum数据库,构建2011至2023年间12个连续房颤患者亚队列,比较直接口服抗凝药(DOAC)与华法林的疗效和安全性。结论提示早期观察性研究可能因优先处方高风险患者而存在偏倚。

要点

  • 早期亚队列中DOAC使用者卒中/TIA病史更常见,提示通道偏倚。
  • 粗卒中风险比从2.66(95%CI 2.00-3.52)降至0.62(0.23-1.67),校正后趋势减弱。
  • 大出血风险未见随时间变化的趋势。

核心结论

  • 早期亚队列中DOAC疗效估计不利,可能因优先处方给高风险患者。
  • 早期观察性研究可能遇到初始偏倚,评估新药需稳健方法学。

研究设计与样本

  • 队列研究,使用临床实践研究数据链Aurum数据库。
  • 创建2011至2023年间12个连续非瓣膜性房颤患者亚队列。
  • 纳入经历1年无处方期后开具DOAC或华法林的患者。

主要发现

  • 早期亚队列中DOAC使用者卒中/短暂性脑缺血发作病史更常见。
  • 后期亚队列中,华法林使用者糖尿病、深静脉血栓/肺栓塞和抗高血压药使用更常见。
  • 华法林使用者中其他心血管疾病史、肾衰竭和利尿剂使用始终较高。
  • 粗卒中风险比(DOAC vs 华法林)从2.66(95%CI 2.00-3.52)变为0.62(0.23-1.67)。
  • 校正分析后趋势减弱,大出血未见此类趋势。

临床怎么用

  • 解读DOAC与华法林比较的早期观察性研究时需警惕通道偏倚。
  • 临床决策应参考校正后的效应估计及随时间变化的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Temporal shifts in patient characteristics can influence comparative treatment effects within a certain indication. We investigated patient characteristics and comparative effectiveness and safety for direct oral anticoagulants (DOACs) and warfarin over the time period where DOACs replaced warfarin as preferred stroke prophylaxis in patients with nonvalvular atrial fibrillation (NVAF). METHODS: We applied the cohort design to the Clinical Practice Research Datalink Aurum and created 12 sequential subcohorts of patients with NVAF between 2011 and 2023. Patients with a DOAC or warfarin prescription following a 1-year prescription-free period were included. Baseline characteristics were compared between subcohorts. Survival analysis was used to evaluate the risk of ischaemic stroke (effectiveness outcome) and major bleeds (safety outcome). RESULTS: We included 207 393 patients with NVAF (45% women, 77% DOAC users, mean age 76 years). In early subcohorts, a history of stroke/transient ischaemic attack was more common among DOAC users. In later subcohorts, diabetes, deep venous thrombosis/pulmonary embolism and antihypertensive use were more common among warfarin users. History of other cardiovascular disease, renal failure and diuretic use were consistently higher among warfarin users. Over time, the crude stroke hazard ratio for DOAC users compared with warfarin users shifted from 2.66 (95% CI 2.00-3.52) to 0.62 (0.23-1.67). This trend was attenuated in adjusted analyses. No such trends were seen for major bleeds. CONCLUSION: DOACs had unfavourable effectiveness estimates in earlier subcohorts, potentially due to preferential prescribing to higher risk patients. Early observational studies may encounter initial biases, underscoring the need for robust methodological approaches when evaluating newly introduced medicines.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. van den Hemel RBLJ, Fiolet ATL, Gamba MA, et al. Comparative treatment effects of direct oral anticoagulants versus warfarin for nonvalvular atrial fibrillation in clinical practice vary over time due to channelling. Br J Clin Pharmacol. 2026. PMID: 42963860. doi:10.1002/bcp.70898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。